Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

NCT03787264 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphoid Leukemia

Interventions

DRUG: Bendamustine
BIOLOGICAL: Obinutuzumab
BIOLOGICAL: Acalabrutinib
BIOLOGICAL: Venetoclax

Sponsor

German CLL Study Group